Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2021

4 - 8 Jun 2021

Virtual, United States of America

ASCO 2021: First AI-based tool for predicting genomic subtypes of pancreatic cancer from histology slides

ASCO 2021: First AI-based tool for predicting genomic subtypes of pancreatic cancer from histology slides

ASCO 2021: New insights on sarcomatoid kidney cancer

ASCO 2021: New insights on sarcomatoid kidney cancer

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

ASCO 2021: Breast cancer patients embrace integrative health during treatment

ASCO 2021: Breast cancer patients embrace integrative health during treatment

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk clear cell RCC

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk...

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line immunotherapy in advanced bladder cancer

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line...

ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2...

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Additional chemotherapy does not offer survival benefit for patients with locally advanced cervical cancer

ASCO 2021: Additional chemotherapy does not offer survival benefit for patients with locally advanced cervical...

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with...

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced nasopharyngeal carcinoma

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced...

ASCO 2021: Targeted radiotherapy offers new treatment option for patients previously treated for metastatic castration-resistant prostate cancer

ASCO 2021: Targeted radiotherapy offers new treatment option for patients previously treated for metastatic...

ASCO 2021: Benefits of immunotherapy combination persist for more than six years in advanced melanoma

ASCO 2021: Benefits of immunotherapy combination persist for more than six years in advanced melanoma

ASCO 2021: Antibody drug conjugate shows promise against non-small cell lung cancer resistant to targeted therapy

ASCO 2021: Antibody drug conjugate shows promise against non-small cell lung cancer resistant to targeted therapy

ASCO 2021: Molecular profiling of tumour tissue can benefit many young patients with cancer, study suggests

ASCO 2021: Molecular profiling of tumour tissue can benefit many young patients with cancer, study suggests

ASCO 2021: Additional cycle of pembrolizumab before surgery improves response rates in locally advanced head and neck cancer

ASCO 2021: Additional cycle of pembrolizumab before surgery improves response rates in locally advanced head and...

ASCO 2021: PET scans following initial treatment help many patients with bulky early-stage Hodgkin lymphoma avoid radiotherapy

ASCO 2021: PET scans following initial treatment help many patients with bulky early-stage Hodgkin lymphoma avoid...

ASCO 2021: Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in phase 2 SPEARHEAD-1 trial

ASCO 2021: Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in...

ASCO 2021: Immunotherapy delays disease recurrence in patients with early-stage, resected non-small cell lung cancer

ASCO 2021: Immunotherapy delays disease recurrence in patients with early-stage, resected non-small cell lung...

ASCO 2021: Dual immunotherapy regimen significantly delays disease progression in patients with advanced melanoma

ASCO 2021: Dual immunotherapy regimen significantly delays disease progression in patients with advanced melanoma

ASCO 2021: Cervical cancer rates drop; other HPV-related cancers are on the rise

ASCO 2021: Cervical cancer rates drop; other HPV-related cancers are on the rise

ASCO 2021: Metabolic inhibitor IACS-6274 shows early anti-tumour effects in underserved patients

ASCO 2021: Metabolic inhibitor IACS-6274 shows early anti-tumour effects in underserved patients

More from ecancer